Litigation Details for Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)
✉ Email this page to a colleague
Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-12-20 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 28:2201dj Declaratory Judgment | Assigned To | Colleen McMahon |
| Jury Demand | None | Referred To | Stewart D. Aaron |
| Parties | AVADEL SPECIALY PHARMACEUTICALS, LLC; FERRING INTERNATIONAL CENTER S.A. | ||
| Patents | 6,613,960; 7,405,203; 7,560,429; 7,579,321; 7,799,761; 7,947,654; 8,802,624; 9,220,747; 9,504,647; 9,539,302 | ||
| Attorneys | James David Weinberger; Kristen Healey Cramer | ||
| Firms | Fross Zelnick Lehrman & Zissu, P.C.; Jones Day (DC) | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Ferring Pharmaceuticals Inc. v. Serenity Pharmaceuticals, LLC (S.D.N.Y. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-04-28 | 1 | Complaint | United States Patent No. 7,405,203, United States Patent No. 7,579,321, and United States Patent No. 7,799,761…Certificate, No. US 7,405,203 C1 (collectively, “the ’203 patent”). The ’203 patent bears the title, “…Application”), which matured into United States Patent No. 7,405,203, and U.S. Application No. 10/706,100 (“… issued United States Patent No. 7,579,321 (“the ’321 patent”). The ’321 patent bears the title, “Pharmaceutical… issued United States Patent No. 7,799,761 (“the ’761 patent”). The ’761 patent bears the title, “Pharmaceutical | External link to document |
| 2018-06-28 | 101 | Answer to Amended Complaint | , United States Patent No. 7,405,203 (the “’203 patent”); 7,579,321 (the “’321 patent”); and 7,799,761…United States Patent Nos. 7,405,203 (the “’203 patent”), and 7,579,321 (the “’321 patent”) (collectively… (INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 55. Counterclaimants incorporate…the ’203 patent on April 12, 2011 by issuing Ex Parte Reexamination Certificate No. US 7,405,203 C1. … (WILLFUL INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 70. Counterclaimants incorporate | External link to document |
| 2018-07-19 | 115 | Answer to Counterclaim | United States Patent Nos. 7,405,203 (“the ’203 patent”) and 7,579,321 (“the ’321 patent”). 9. … (INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 55. Ferring incorporates by… (WILLFUL INFRINGEMENT OF U.S. PATENT NO. 7,405,203) 70. Ferring incorporates by…Certificate No. US 7,405,203 C1 on April 12, 2011. Ferring states that the claims of the ’203 patent are invalid…issued Ex Parte Reexamination Certificate No. US 7,405,203 C1 on April 12, 2011. Ferring denies the remaining | External link to document |
| 2018-09-19 | 201 | Declaration | version of the original filed claims for U.S. Patent No. 7,405,203, # 2 Exhibit 18 - certified version of the… the original filed claims for U.S. Patent No. 7,579,321, # 3 Exhibit 19 - certified version of the Preliminary…December 2017 21 August 2020 1:17-cv-09922 Patent None District Court, S.D. New York | External link to document |
| 2017-07-07 | 22 | Redacted Document | United States Patent No. 7,405,203, United States Patent No. 7,579,321, and United States Patent No. 7,799,761…Certificate, No. US 7,405,203 C1 (collectively, “the ’203 patent”). The ’203 patent bears the title, “…Application”), which matured into United States Patent No. 7,405,203, and U.S. Application No. 10/706,100 (“… issued United States Patent No. 7,579,321 (“the ’321 patent”). The ’321 patent bears the title, “Pharmaceutical… issued United States Patent No. 7,799,761 (“the ’761 patent”). The ’761 patent bears the title, “Pharmaceutical | External link to document |
| 2018-10-01 | 222 | Memorandum of Law in Support of Motion | conduct of U.S. Patent Nos. 7,405,203 (“the ’203 patent”), 7,579,321 (“the ’321 patent”), and 7,799,761…7,799,761 (“the ’761 patent”) (collectively, “patents in suit”). Inequitable conduct in patent cases is results…the ’203 patent only. Corresponding citations can be found in the ’321 patent and ’761 patent. …results in the patents in suit should being held unenforceable because the patent applicant deceived the…the U.S. Patent and Trademark Office (“PTO”) when obtaining the patents in suit. Ferring alleged inequitable | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
